Friday, 07 August 2020

BIORx to hold India's first bio-acceleration program

27 August 2013 | News | By BioSpectrum Bureau

BIORx Venture Advisors' (BIORx) bio-acceleration program will be held from September 21-23, 2013 at New Delhi, India

BIORx Venture Advisors' (BIORx) bio-acceleration program will be held from September 21-23, 2013 at New Delhi, India

New Delhi: BIORx Venture Advisors (BIORx) is going to launch India's first dedicated bio-acceleration program with the theme 'Transformation of technological innovation into business success', from 9 am on September 21, 2013-to-5 pm on September 23, 2013, at New Delhi, India.

BIORx Venture Advisors, which is a boutique investment bank dedicated to provide financing and strategic partnership solutions to the life sciences Industry in India, is organizing the event in order enable technologists to become successful business women/men in the life sciences sector.

The program has been devised for working executives who aspire to accelerate the path of their discovery to the marketplace. BIORx has teamed up with the National Institute of Immunology (NII), an autonomous institution of the Department of Biotechnology, Government.of India, and with the Foundation for Innovation in Technology Transfer (FITT) of IIT-Delhi (as an incubation partner) to enable the successful execution of these Ideas to marketplace.

The three also signed up a tri-partite memorandum of understanding (MOU) to strengthen the ecosystem further to accelerate the commercializing of the life sciences innovation.

BIORx earlier conducted master class on venture capital and private equity in life sciences under the aegis of BIOAsia at Hyderabad, India. The workshop was supported by BIRAC and was attended by 30 CEOs and CTOs from various life sciences organization.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls